(Q43609687)

25 November 2017

title

Temozolomide and 13-cis retinoic acid in patients with anaplastic gliomas: a prospective single-arm monocentric phase-II study (RNOP-05). (English)

1 reference

25 November 2017

0 references

1 reference

10

Ulrich Bogdahn

1 reference

25 November 2017

11

Peter Hau

1 reference

25 November 2017

6

Martin Proescholdt

1 reference

25 November 2017

7

Alexander Brawanski

1 reference

25 November 2017

5

Michael Weller

1 reference

25 November 2017

9

Wolfgang Wick

1 reference

25 November 2017

2

Christina Pascher

1 reference

25 November 2017

Oliver Grauer

1

1 reference

25 November 2017

Christian Hartmann

series ordinal

3

1 reference

25 November 2017

Florian Zeman

series ordinal

4

1 reference

25 November 2017

Thorsten Pietsch

series ordinal

8

1 reference

25 November 2017

publication date

4 March 2011

1 reference

Journal of Neuro-Oncology

25 November 2017

published in

1 reference

25 November 2017

volume

104

1 reference

25 November 2017

issue

3

1 reference

25 November 2017

page(s)

801-809

1 reference

https://scigraph.springernature.com/pub.10.1007/s11060-011-0548-y

25 November 2017

exact match

0 references

cites work

Retinoids inhibit human glioma cell proliferation and migration in primary cell cultures but not in established cell lines

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0548-Y

Effects of a novel synthetic retinoid on malignant glioma in vitro: inhibition of cell proliferation, induction of apoptosis and differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0548-Y

Retinoic acid increases proliferation rate of GL-15 glioma cells, involving activation of STAT-3 transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0548-Y

Retinoids induced astrocytic differentiation with down regulation of telomerase activity and enhanced sensitivity to taxol for apoptosis in human glioblastoma T98G and U87MG cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0548-Y

Differentiation therapy exerts antitumor effects on stem-like glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0548-Y

13-Cis-retinoic acid: pharmacology, toxicology, and clinical applications for the prevention and treatment of human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0548-Y

Maintenance therapy with 13-cis retinoid acid in high-grade glioma at complete response after first-line multimodal therapy--a phase-II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0548-Y

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0548-Y

Temozolomide as first-line agent in treating high-grade gliomas: phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0548-Y

Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0548-Y

Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0548-Y

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0548-Y

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0548-Y

Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0548-Y

A phase II study of concurrent temozolomide and cis-retinoic acid with radiation for adult patients with newly diagnosed supratentorial glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0548-Y

NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0548-Y

The 2007 WHO classification of tumours of the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0548-Y

Mutations of the PIK3CA gene are rare in human glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0548-Y

Multiplex ligation-dependent probe amplification: a diagnostic tool for simultaneous identification of different genetic markers in glial tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0548-Y

Analysis of the IDH1 codon 132 mutation in brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0548-Y

MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0548-Y

Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0548-Y

1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0548-Y

Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0548-Y

A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0548-Y

1p36 is a preferential target of chromosome 1 deletions in astrocytic tumours and homozygously deleted in a subset of glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0548-Y

Two types of chromosome 1p losses with opposite significance in gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0548-Y

Molecular genetic analysis of oligodendroglial tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0548-Y

A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy

21 January 2018

1 reference

12 December 2020

Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy

1 reference

12 December 2020

White matter changes are correlated significantly with radiation dose. Observations from a randomized dose-escalation trial for malignant glioma (Radiation Therapy Oncology Group 83-02)

1 reference

12 December 2020

Response criteria for phase II studies of supratentorial malignant glioma

1 reference

12 December 2020

A phase II trial of primary temozolomide in patients with grade III oligodendroglial brain tumors

1 reference

12 December 2020

Pharmacokinetics of all-trans retinoic acid, 13-cis retinoic acid, and fenretinide in plasma and brain of Rat.

1 reference

12 December 2020

Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group

1 reference

12 December 2020

Treatment of recurrent malignant gliomas with high-dose 13-cis-retinoic acid.

1 reference

12 December 2020

Pharmacokinetics of 3-methyl-(triazen-1-yl)imidazole-4-carboximide following administration of temozolomide to patients with advanced cancer

1 reference

12 December 2020

Transcript map of the 3.7-Mb D19S112-D19S246 candidate tumor suppressor region on the long arm of chromosome 19.

1 reference

12 December 2020

Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia

1 reference

12 December 2020

10.1007/S11060-011-0548-Y

Identifiers

DOI

1 reference

Dimensions Publication ID

25 November 2017

1023315936

0 references

1 reference